Aqvesme is a drug owned by Agios Pharmaceuticals Inc. It is protected by 6 US drug patents filed in 2026 out of which none have expired yet. Aqvesme's patents have been open to challenges since 17 February, 2026. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 31, 2041. Details of Aqvesme's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11254652 | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(12 years from now) | Active |
| USRE49582 | Therapeutic compounds and compositions |
Feb, 2031
(5 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11878049 | Mitapivat therapy and modulators of cytochrome P450 |
Jul, 2041
(15 years from now) | Active |
| US9193701 | Pyruvate kinase activators for use in therapy |
Oct, 2032
(6 years from now) | Active |
| US10632114 | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | Active |
| US9682080 | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Aqvesme is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Aqvesme's family patents as well as insights into
ongoing legal events
on those patents.
Aqvesme's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Aqvesme's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 31, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Aqvesme Generics:
There are no approved generic versions for Aqvesme as of now.
Alternative Brands for Aqvesme
There are several other brand drugs using the same active ingredient (Mitapivat Sulfate) as Aqvesme. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Agios Pharms Inc |
|
About Aqvesme
Aqvesme is a drug owned by Agios Pharmaceuticals Inc. Aqvesme uses Mitapivat Sulfate as an active ingredient. Aqvesme was launched by Agios in 2025.
Approval Date:
Aqvesme was approved by FDA for market use on 23 December, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Aqvesme is 23 December, 2025, its NCE-1 date is estimated to be 17 February, 2026.
Active Ingredient:
Aqvesme uses Mitapivat Sulfate as the active ingredient. Check out other Drugs and Companies using Mitapivat Sulfate ingredient
Dosage:
Aqvesme is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG BASE | TABLET | Prescription | ORAL |